Targeting MicroRNAs in CKD: Leveraging RNA Biology for Precision Therapeutics in Kidney Disease
Time: 2:00 pm
day: Day Two PM
Details:
- Explore how Regulus Therapeutics’ antisense oligonucleotide platform targets microRNAs to regulate gene expression in CKD pathways like fibrosis and inflammation, aiming to limit off-target effects and directly impact cellular mechanisms
- Discuss advancements in selective kidney targeting, where oligonucleotides preferentially bind to microRNAs in renal cells, achieving localized therapeutic action and minimizing systemic effects
- Review preclinical and clinical data on Regulus’ focus on orphan kidney diseases, including ADPKD, and highlight the potential of microRNA-targeted therapies as disease-modifying treatments in CKD